View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsIO Biotech 過去の業績過去 基準チェック /06IO Biotechの収益は年平均-18.4%で減少しているが、Biotechs業界はgrowingで30%年平均の収益となった。主要情報-18.37%収益成長率84.84%EPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率-9,698.02%ネット・マージンn/a前回の決算情報30 Sep 2025最近の業績更新更新なしすべての更新を表示Recent updatesIO Biotech, Inc. Filed for BankruptcyMar 31IO Biotech, Inc. Receives Notice of Non-Compliance with Nasdaq Listing StandardsFeb 14IO Biotech Implements Significant Workforce Reduction as Part of Cost-Containment Measures While Exploring Strategic AlternativesJan 30Price target decreased by 12% to US$2.18 Jan 27Price target decreased by 49% to US$2.46 Dec 29IO Biotech, Inc. Receives Notice of Non-Compliance with Nasdaq Minimum Bid Price Listing RuleDec 22IO Biotech Announces Publication of Five-Year Clinical Outcomes of Phase 1/2 Trial in Nature CommunicationsDec 16IO Biotech, Inc. Announces Executive ChangesNov 22IO Biotech Presents Phase 3 Results for Cylembio Plus KEYTRUDA (Pembrolizumab) in First-Line Advanced Melanoma at ESMO 2025Oct 21IO Biotech Provides Update Following Pre-BLA Meeting with FDASep 30New minor risk - Market cap size Sep 23Price target decreased by 11% to US$8.00 Sep 10IO Biotech Announces Topline Results of Pivotal Phase 3 Trial of Cylembio in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaAug 12New major risk - Share price stability Aug 11IO Biotech's Phase 3 Trial Fails To Deliver Aug 11New minor risk - Share price stability May 31Price target increased by 12% to US$9.50 May 14IO Biotech, Inc., Annual General Meeting, Jun 05, 2025Apr 28IO Biotech Presents New Data At AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer VaccinesIO102-IO103 and IO170Apr 26New minor risk - Share price stability Apr 09Can IO Biotech (NASDAQ:IOBT) Afford To Invest In Growth?Apr 02IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, Arginase 1-Targeting Therapeutic Cancer Vaccine CandidateFeb 05IO Biotech Completes Enrollment in Its Neoadjuvant/Adjuvant Phase 2 Basket Trial (IOB-032/PN-E40)Jan 09IO Biotech, Inc. Receives Nasdaq Non-Compliance Letter Regarding Minimum Bid Price RequirementDec 29Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn SituationDec 17IO Biotech, Inc. Announces Data from the NSCLC Cohort in the Phase 2 Basket Trial of IO102-IO103Nov 08IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-Line Treatment of Advanced Head and Neck CancerSep 14Price target decreased by 13% to US$8.50 Sep 04IO Biotech, Inc. Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaAug 31New major risk - Financial position Aug 14New minor risk - Share price stability Jul 25We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn RateJun 12IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of DirectorsApr 28IO Biotech, Inc., Annual General Meeting, Jun 06, 2024Apr 26New minor risk - Market cap size Apr 16IO Biotech Announces Marjan Shamsaei as Senior Vice PresidentApr 15IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103Apr 10IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business OfficerApr 05IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual MeetingMar 07New major risk - Revenue and earnings growth Mar 07New minor risk - Market cap size Feb 22We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth CarefullyFeb 10IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialDec 22High number of new directors Dec 01IO Biotech Appoints Helen Collins, Md, to Its Board of DirectorsNov 14IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced MelanomaNov 11New minor risk - Share price stability Oct 29IO Biotech, Inc. Announces Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) CongressOct 23New major risk - Revenue and earnings growth Sep 22New major risk - Shareholder dilution Aug 13Price target decreased by 15% to US$9.67 Aug 13IO Biotech, Inc. Appoints Heidi Hunter to Its Board of DirectorsAug 12IO Biotech, Inc. announced that it expects to receive $75.057935 million in funding from a group of investorsAug 08IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer CenterJul 29IO Biotech, Inc. Announces Executive ChangesJul 21New minor risk - Share price stability Jun 16IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment MilestoneJun 15We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth CarefullyJun 15IO Biotech, Inc. Appoints Christine Richter as Senior Vice President, Commercial and Program LeadJun 02Chief Financial Officer recently bought US$58k worth of stock Mar 21IO Biotech Appoints Devin Smith as General Counsel and Chief Compliance OfficerJan 24We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth CarefullyJan 20Price target decreased to US$17.50 Nov 16IO Biotech, Inc. Announces Appointment of Amy Sullivan as Chief Financial OfficerOct 14IO Biotech names new CFO Oct 13We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn RateSep 27IO Biotech GAAP EPS of -$0.64 Aug 11We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn RateJun 14IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced MelanomaMay 19IO Biotech, Inc. Announces Executive ChangesMay 15+ 1 more updateHigh number of new directors Apr 27High number of new directors Apr 21IO Biotech, Inc. Announces its Two Directors Not Stand for Re-ElectionApr 15IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual MeetingApr 09IO Biotech, Inc. Announces Appointment of David V. Smith to Board of DirectorsMar 06We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth CarefullyFeb 25収支内訳IO Biotech の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqGS:IOBT 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Sep 250-88246830 Jun 250-104257431 Mar 250-98247431 Dec 240-95247130 Sep 240-90247230 Jun 240-88247031 Mar 240-88237031 Dec 230-86246830 Sep 230-80236030 Jun 230-74235331 Mar 230-71244931 Dec 220-71244730 Sep 220-74234930 Jun 220-65214331 Mar 220-87173831 Dec 210-75113030 Sep 210-5661630 Jun 210-5441531 Mar 210-1721031 Dec 200-1528質の高い収益: IOBTは現在利益が出ていません。利益率の向上: IOBTは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: IOBTは利益が出ておらず、過去 5 年間で損失は年間18.4%の割合で増加しています。成長の加速: IOBTの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: IOBTは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 40.2% ) と比較することは困難です。株主資本利益率高いROE: IOBTは現在利益が出ていないため、自己資本利益率 ( -9698.02% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/03/30 06:52終値2026/03/30 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋IO Biotech, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Christopher HowertonJefferies LLCRoger SongJefferies LLC
IO Biotech Implements Significant Workforce Reduction as Part of Cost-Containment Measures While Exploring Strategic AlternativesJan 30
IO Biotech Announces Publication of Five-Year Clinical Outcomes of Phase 1/2 Trial in Nature CommunicationsDec 16
IO Biotech Presents Phase 3 Results for Cylembio Plus KEYTRUDA (Pembrolizumab) in First-Line Advanced Melanoma at ESMO 2025Oct 21
IO Biotech Announces Topline Results of Pivotal Phase 3 Trial of Cylembio in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaAug 12
IO Biotech Presents New Data At AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer VaccinesIO102-IO103 and IO170Apr 26
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, Arginase 1-Targeting Therapeutic Cancer Vaccine CandidateFeb 05
IO Biotech Completes Enrollment in Its Neoadjuvant/Adjuvant Phase 2 Basket Trial (IOB-032/PN-E40)Jan 09
IO Biotech, Inc. Announces Data from the NSCLC Cohort in the Phase 2 Basket Trial of IO102-IO103Nov 08
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-Line Treatment of Advanced Head and Neck CancerSep 14
IO Biotech, Inc. Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaAug 31
IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103Apr 10
IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual MeetingMar 07
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialDec 22
IO Biotech, Inc. Announces Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) CongressOct 23
IO Biotech, Inc. announced that it expects to receive $75.057935 million in funding from a group of investorsAug 08
IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer CenterJul 29
IO Biotech, Inc. Appoints Christine Richter as Senior Vice President, Commercial and Program LeadJun 02
IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced MelanomaMay 19
IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual MeetingApr 09